PBSC chimeric mice
| Group . | Mice . | No. . |
|---|---|---|
| Control | BXSB (untreated, age-matched) | 10 |
| BXSB→BXSB | 16 | |
| BALB/c→B6 | 5 | |
| B6+BXSB→BXSB | 20 | |
| Prevention | BALB/c→BXSB | 10 |
| BALB/c+BXSB→BXSB | 20 | |
| Transfer | BXSB→BALB/c | 20 |
| BXSB+BALB/c→BALB/c | 20 |
| Group . | Mice . | No. . |
|---|---|---|
| Control | BXSB (untreated, age-matched) | 10 |
| BXSB→BXSB | 16 | |
| BALB/c→B6 | 5 | |
| B6+BXSB→BXSB | 20 | |
| Prevention | BALB/c→BXSB | 10 |
| BALB/c+BXSB→BXSB | 20 | |
| Transfer | BXSB→BALB/c | 20 |
| BXSB+BALB/c→BALB/c | 20 |
Low-density PB cells from the splenectomized donor mice were collected on day 7 after Ara-C plus G-CSF treatment, and T cells were depleted magnetically with the use of anti–Thy-1.2 mAb plus immunomagnetic beads. At 8 weeks of age, recipient mice were lethally irradiated and were injected intravenously with these PBSCs.